| Status | Protocol Id | Protocol Title | PHASE | Sponsor | CRO | Recruitment |
| SURVIVAL FOLLOW-UP | CABL001J12301 | A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase. | III | NOVARTIS | N/A | RGCI COMPLETED |
| Protocol Id | PI | Protocol Title | PHASE | Sponsor | CRO/ Other | RECRUITMENT |
| HQP1351CG301 | Dr. Dinesh Bhurani | A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia(POLARIS-2) | III | Ascentage | IQVIA | RGCI UPCOMING |